Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07220060 + Vepdegestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07220060 | PF 07220060|PF07220060 | CDK4 Inhibitor 17 | PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary). | |
Vepdegestrant | ARV471|ARV 471|PF 07850327|PF07850327|PF-07850327|ARV-471 | Hormone - Anti-estrogens 29 | Vepdegestrant (ARV-471) is a bifunctional molecule that targets the estrogen receptor (ESR1), including ESR1 variants, for proteolytic degradation resulting in reduced target gene expression and potentially leading to reduced cell proliferation and inhibition of tumor growth (Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-18, PMID: 32829249). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06206837 | Phase I | PF-07220060 + Vepdegestrant | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | Recruiting | USA | FRA | ESP | CAN | BEL | 3 |